Russian Direct Investment Fund and the ChemRar Group to Deliver 60,000 Courses of the First COVID-19 Drug Registered in Russia
Posted on 06/01/2020
The Russian Direct Investment Fund (RDIF) and the ChemRar Group plans to deliver 60,000 courses of Avifavir to Russian hospitals in June 2020. Avifavir is Russia’s first COVID-19 drug and has shown high efficacy in treating patients with coronavirus during clinical trials. Avifavir has received a registration certificate from the Ministry of Health of the Russian Federation.
Avifavir has become the first Favipiravir-based drug in the world approved for the treatment of COVID-19. Favipiravir is sold under the brand name Avigan and it is an antiviral medication used to treat influenza in Japan. According to the RDIF, “The drug proved to be highly effective during the clinical trials involving I.M. Sechenov First Moscow State Medical University, Lomonosov Moscow State University and other medical and academic institutions.”
Thus, Avifavir has become the first Favipiravir-based drug in the world approved for the treatment of COVID-19.
